Treatment of melasma, a hyperpigmentation
disorder, remains a challenge. The primary
objective of two 8-week, multicenter, randomized, investigator-blind studies was to compare
the efficacy and safety of a hydrophilic
cream formulation containing tretinoin 0.05%,
hydroquinone 4.0%, and fluocinolone acetonide
0.01% (RAHQFA) with the dual-combination
agents tretinoin plus hydroquinone (RAHQ),
tretinoin plus fluocinolone acetonide (RAFA),